PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Cannabis (medicinal) - Pain

PAD Profile : Cannabis (medicinal) - Pain

Keywords :
nabilone, dronabinol, tetrahydrocannabinol, THC, CBMP, cannabidiol, CBD, Cancard, medicinal cannabis, cannabis-based products for medicinal use, CBPM, Sativex, Epidyolex

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
CD
U
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 November 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

NHS England guidance to support clinicians on the prescribing of cannabis-based products for medicinal use:

https://www.england.nhs.uk/medicines-2/support-for-prescribers/cannabis-based-products-for-medicinal-use/

16 January 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee (APC) recommends that Cannabis based medicinal products (CBMP) for chronic pain are given a BLACK traffic light status in line with NICE NG144, which states that these products (nabilone, dronabinol, Tetrahydrocannabinol (THC) & the combination of THC & cannabidiol (Sativex) should not be offered to manage chronic pain in adult patients unless as part of a clinical trial.

The APC concurred that there is likely to be even less evidence available for children and young people, so the recommendation should apply to all ages. 

Providers (NHS and non-NHS) will be solely liable for clinical governance, prescribing responsibility and costs of all prescriptions of cannabis-based medicinal products when it is used off-label i.e. outside of its marketing authorisation. Shared care will not be supported for an off-label uses.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Associated BNF Codes

04. Central Nervous System
04.08.01. Control of epilepsy
10. Musculoskeletal and Joint Diseases
10.02.02. Skeletal muscle relaxants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More